Stallergenes Greer plc is very pleased to announce that it has been authorized to restart the manufacturing of its Named Patient Products (NPP) after a temporary suspension at its Stallergenes SAS plant in Antony, France. Products such as STALORAL® will be progressively available again to patients, starting with the most prevalent allergens.

Stallergenes Greer has already started the manufacturing and distribution of ORALAIR® and ALYOSTAL® Venom as of Feb 1st, 2016.

The temporary suspension was the result of issues with Stallergenes Greer’s IT interfaces which are now fully resolved. This suspension lift enables the Company to fully resume its activities, according to a progressive restart plan.

Stallergenes Greer is more than ever committed to build on experience to offer best-in-class solutions to allergy specialists and allergic patients, underpinned by a Quality driven approach across industrial Operations. To this end, they are fully engaged to work with international regulators in the journey to bring Allergy Immunotherapy to the highest standards.

If you are a patient it is important that you refer to your doctor who prescribed your allergy immunotherapy and who is in the best position to provide personalized medical advices .

We are working with those affected to minimise the impact on care and treatment. Please contact your local representative (details can be found here), if you are requesting further information.

Any adverse events should be reported to your national medical authority or to the Stallergenes Greer representative in your country.

Contact information can be accessed at:

Last updated on: 04/10/2016

Cookies Management